Sunday, August 18, 2024 7:27:01 PM
They have shares to push and dilute. Maybe they can RS two more times. Can you believe they went from 1.2 billion shares down to 7.7 million, back to 78 million, then down to 1.2 million? Pump, dilute, split and repeat, the cycle continues. If the company folded insiders risk nothing, walking away with millions from over the years and on to their next venture, can the same be said for the retail class B shareholders off of who's backs this company was built?
Bearish
Recent QNTM News
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/02/2026 12:30:03 PM
- Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied • GlobeNewswire Inc. • 04/02/2026 12:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 04/01/2026 12:02:04 PM
- Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis • GlobeNewswire Inc. • 04/01/2026 12:02:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/30/2026 11:50:09 AM
- Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis • GlobeNewswire Inc. • 03/30/2026 11:50:00 AM
- Quantum Biopharma Provides Corporate Update • GlobeNewswire Inc. • 03/27/2026 11:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/27/2026 12:10:03 PM
- Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status • GlobeNewswire Inc. • 03/27/2026 12:10:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/26/2026 12:00:10 PM
- Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis • GlobeNewswire Inc. • 03/26/2026 12:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 03/23/2026 12:24:03 PM
- Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd • GlobeNewswire Inc. • 03/23/2026 12:24:00 PM
- Quantum Biopharma Announces Closing of Initial Tranche of Private Placement Offering • GlobeNewswire Inc. • 03/20/2026 11:35:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/11/2026 11:55:00 PM
- Quantum BioPharma Provides Corporate Update • GlobeNewswire Inc. • 03/10/2026 11:45:00 PM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 02/03/2026 02:19:46 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/23/2025 01:00:05 PM
- Quantum Biopharma Announces Completion of Dosing in 180-Day Repeated Dose Oral Toxicity and Toxicokinetic Studies for Lucid-21-302 (Lucid-MS) • GlobeNewswire Inc. • 12/23/2025 01:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 09:23:02 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 12/22/2025 08:48:55 PM
- World Renowned Law Firm Grant & Eisenhofer Files Class Action Lawsuit Against Canadian Banks CIBC and RBC Alleging Illegal Stock Market Manipulation of Quantum BioPharma Shares • ACCESS Newswire • 12/22/2025 02:00:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 12/22/2025 12:00:04 PM
- Form 6-K/A - Report of foreign issuer [Rules 13a-16 and 15d-16]: [Amend] • Edgar (US Regulatory) • 12/11/2025 03:14:49 PM
- Quantum BioPharma Announces Closing of Private Placement & Provides Corporate Update • Newsfile • 12/11/2025 01:00:00 AM
